Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016', provides in depth analysis on Cell Division Protein FtsZ (ftsz) targeted pipeline therapeutics. The report provides comprehensive information on the Cell Division Protein FtsZ (ftsz), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cell Division Protein FtsZ (ftsz) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Cell Division Protein FtsZ (ftsz) - The report reviews Cell Division Protein FtsZ (ftsz) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Cell Division Protein FtsZ (ftsz) targeted therapeutics and enlists all their major and minor projects - The report assesses Cell Division Protein FtsZ (ftsz) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Cell Division Protein FtsZ (ftsz) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Cell Division Protein FtsZ (ftsz) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cell Division Protein FtsZ (ftsz) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cell Division Protein FtsZ (ftsz) Overview 6 Therapeutics Development 7 Cell Division Protein FtsZ (ftsz) - Products under Development by Stage of Development 7 Cell Division Protein FtsZ (ftsz) - Products under Development by Therapy Area 8 Cell Division Protein FtsZ (ftsz) - Products under Development by Indication 9 Cell Division Protein FtsZ (ftsz) - Pipeline Products Glance 10 Early Stage Products 10 Cell Division Protein FtsZ (ftsz) - Products under Development by Companies 11 Cell Division Protein FtsZ (ftsz) - Products under Development by Universities/Institutes 13 Cell Division Protein FtsZ (ftsz) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Cell Division Protein FtsZ (ftsz) - Companies Involved in Therapeutics Development 20 Gero Corp 20 TAXIS Pharmaceuticals, Inc. 21 Vichem Chemie Research Ltd. 22 Cell Division Protein FtsZ (ftsz) - Drug Profiles 23 BIZ-20131 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 BIZ-20132 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 BIZ-20133 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 chrysophaentin - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 SBP-17GA20 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecules to Inhibit FtsZ for MRSA Infections - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Inhibit FtsZ for Tuberculosis - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 TXA-497 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 TXA-709 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 VCC-34236501 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 VCC-40402101 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 VCC-59946013 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Cell Division Protein FtsZ (ftsz) - Dormant Projects 37 Cell Division Protein FtsZ (ftsz) - Featured News & Press Releases 38 Jun 13, 2016: Experimental Antibiotic Treats Deadly MRSA Infection 38 Sep 18, 2015: TAXIS Pharmaceuticals Demonstrates Synergistic Efficacy Against MRSA And Low Resistance Frequency With TXA709/Cefdinir Combination 39 Jun 05, 2015: TAXIS Pharmaceuticals Announces Publication of Data Demonstrating Potential Viability of TXA709 in Combating Antibiotic Resistance 40 Apr 27, 2015: TAXIS Pharmaceuticals Demonstrates Clinical Potential of TXA709 in Combating Antibiotic Resistance 41 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Products under Development by Companies, H2 2016 12 Number of Products under Investigation by Universities/Institutes, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Stage and Mechanism of Action, H2 2016 16 Number of Products by Stage and Route of Administration, H2 2016 18 Number of Products by Stage and Molecule Type, H2 2016 19 Pipeline by Gero Corp, H2 2016 20 Pipeline by TAXIS Pharmaceuticals, Inc., H2 2016 21 Pipeline by Vichem Chemie Research Ltd., H2 2016 22 Dormant Projects, H2 2016 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
